Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZGR Regimen as First-Line Therapy for Mantle Cell Lymphoma
NCT07261163Phase 2Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Dec 2025
- Primary completion
- Jul 2027
- Modality
- Fragment-Derived Small Molecules, Antibody Conjugates, Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zanubrutinib, obinutuzumab and lenalidomide in mantle cell lymphoma (MCL), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Complete Response Rate at 24 weeks. Started Dec 2025; status: recruiting.
02
Drugs
zanubrutinibobinutuzumablenalidomide
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT07261163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07261163.